<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Seventy-seven patients (age 12 to 46 years) who underwent allogeneic marrow transplantation for <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancy</z:e> or <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and who had grade II to IV <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> despite <z:chebi fb="0" ids="44185">methotrexate</z:chebi> prophylaxis were randomly assigned to receive <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> 2 mg/kg per day intravenously (n = 39) or <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> (n = 38) either 12 to 15 mg/kg per day orally or 3 to 5 mg/kg per day intravenously </plain></SENT>
<SENT sid="1" pm="."><plain>In both groups, clinical and histologic evidence of <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> was detected at medians of 16 and 25 days, respectively </plain></SENT>
<SENT sid="2" pm="."><plain>Drugs were given for a minimum of 14 days unless significant deterioration occurred </plain></SENT>
<SENT sid="3" pm="."><plain>If <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> did not improve with this therapy, treatment with a second agent was initiated </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment responses were scored after reviewing clinical and laboratory data collected before, during, and after the 14-day treatment period </plain></SENT>
<SENT sid="5" pm="."><plain>Possible scores were as follows: -1, worse; 0, no change; + 1, improvement in one organ system (skin, liver, gut) with no deterioration in the other two; +2, complete resolution of <z:hpo ids='HP_0000001'>all</z:hpo> involved systems </plain></SENT>
<SENT sid="6" pm="."><plain>The median response score among 39 methylprednisolone-treated patients was 0 </plain></SENT>
<SENT sid="7" pm="."><plain>Sixteen patients (41 percent) showed response to treatment, 11 with partial and five with complete response </plain></SENT>
<SENT sid="8" pm="."><plain>The median response score among 38 cyclosporine-treated patients was +1 </plain></SENT>
<SENT sid="9" pm="."><plain>Twenty-three patients (61 percent) showed response to treatment, 15 with partial and eight with complete response (p = 0.039) </plain></SENT>
<SENT sid="10" pm="."><plain>Twenty patients receiving <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> and 18 receiving <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> required additional therapy </plain></SENT>
<SENT sid="11" pm="."><plain>The incidence of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> was similar in both groups </plain></SENT>
<SENT sid="12" pm="."><plain>It developed in <z:hpo ids='HP_0000001'>all</z:hpo> nonresponding patients at risk who had received secondary therapy </plain></SENT>
<SENT sid="13" pm="."><plain>Among responding patients (scores +1 or +2) who were not given additional treatment, <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> developed in eight of 11 (72 percent) receiving <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> and five of ten (50 percent) receiving <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> </plain></SENT>
<SENT sid="14" pm="."><plain>Survival beyond 17 months was similar in the two groups (28 percent and 24 percent, respectively) </plain></SENT>
<SENT sid="15" pm="."><plain>These data suggest that <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> is a useful agent for the treatment of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e>, comparable in its efficacy to <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> </plain></SENT>
</text></document>